Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELEVANCE: Lenalidomide + Rituximab vs Chemotherapy in Untreated Follicular Lymphoma
NCT01650701Phase 3Completed
- Sponsor
- LYSARC
- Start
- Feb 2012
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of lenalidomide in follicular lymphoma (FL), sponsored by LYSARC. Started Feb 2012; status: completed.
02
Drugs
lenalidomide
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT01650701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01650701.